Lignin in Treatment of Helicobacter Pylori Infection

The goal of this clinical trial is to learn if drug hydrolyzed lignin works to treat H pylori infection in adults. It will also learn about the safety of drug lignin n the sitting of H pylori infection, and if it halts the side effects associated with H pylori triple therapy. The main questions it aims to answer are: * Does drug hydrolyzed lignin improve the H pylori eradiation rate when it is added to the standard triple therapy used in treatment of H pylori? * What medical problems do participants experience when taking drug hydrolyzed lignin? Researchers will compare drug hydrolyzed lignin to a placebo (a look-alike substance that contains no drug) to see if drug hydrolyzed lignin works to treat H pylori. Participants will: * Take drug hydrolyzed lignin or a placebo every day for 2 weeks beside the standard triple therapy * Visit the clinic once every 1 week for checkup and questionnaire filling * Check for H pylori eradication after treatment

Inclusion Criteria: * Age: Adults, older than 18. * Gender: all * Patient with confirmed diagnosis of H pylori for the first time * H pylori treatment naive patients * Welling to participate Exclusion Criteria: * Patients with failed H pylori eradication * Allergy to the used medications * Patients with other structural bowel diseases e.g. celiac disease, ischemic colitis, IBD, chronic diarrhea * General debilitating diseases e.g. decompensated cirrhosis, renal failure